Early differences in cytokine production by severity of coronavirus disease 2019

…, T Nagano, T Kiriu, M Nishimura… - The Journal of …, 2021 - academic.oup.com
Most patients with coronavirus disease 2019 (COVID-19) experience asymptomatic disease
or mild symptoms, but some have critical symptoms requiring intensive care. It is important …

Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells

M Nishimura, K Sato, T Okada, I Yoshiya… - The Journal of the …, 1998 - pubs.asahq.org
Background Ketamine has been characterized as having psychotomimetic and
sympathomimetic effects. These symptoms have raised the possibility that ketamine affects …

Assessment of neutralizing antibody response against SARS-CoV-2 variants after 2 to 3 doses of the BNT162b2 mRNA COVID-19 vaccine

…, Y Kurahashi, S Sutandhio, M Nishimura… - JAMA network …, 2022 - jamanetwork.com
Importance Although 2 and 3 doses of vaccine have been implemented against the SARS-CoV-2
pandemic, the level of immunity achieved by these additional vaccinations remains …

[HTML][HTML] Human monoclonal antibodies broadly neutralizing against influenza B virus

…, N Kawashita, A Du, T Sasaki, M Nishimura… - PLoS …, 2013 - journals.plos.org
Influenza virus has the ability to evade host immune surveillance through rapid viral genetic
drift and reassortment; therefore, it remains a continuous public health threat. The …

[HTML][HTML] Synthesis and assessment of copper-based nanoparticles as a surface coating agent for antiviral properties against SARS-CoV-2

…, RR Prasetya, K Rahardjo, M Nishimura… - Scientific Reports, 2022 - nature.com
To halt the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
governments around the world have imposed policies, such as lockdowns, mandatory mask …

[HTML][HTML] Seroepidemiological study of SARS-CoV-2 infection in east Java, Indonesia

…, Juniastuti, E Gunawan, K Furukawa, M Nishimura… - Plos one, 2021 - journals.plos.org
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has led to a global pandemic, including Indonesia. However, there …

[HTML][HTML] Cross-neutralizing breadth and longevity against SARS-CoV-2 variants after infections

…, H Ohkita, S Nakamura, M Nishimura… - Frontiers in …, 2022 - frontiersin.org
Background Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the virus
responsible for the Coronavirus Disease 2019 (COVID-19) pandemic. The emergence of …

Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of …

T Sasaki, C Setthapramote, T Kurosu, M Nishimura… - Antiviral research, 2013 - Elsevier
Public health concern about dengue diseases, caused by mosquito-borne infections with
four serotypes of dengue virus (DENV-1–DENV-4), is escalating in tropical and subtropical …

Regional distribution of GABA transporter 1 (GAT1) mRNA in the rat brain: comparison with glutamic acid decarboxylase67 (GAD67) mRNA localization

M Yasumi, K Sato, S Shimada, M Nishimura… - Molecular brain …, 1997 - Elsevier
The mRNA expression of GABA transporter 1 (GAT1) was investigated in the rat brain by in
situ hybridization histochemistry using an oligonucleotide probe specific to the mRNA. The …

Cross-neutralizing activity against SARS-CoV-2 variants in COVID-19 patients: comparison of 4 waves of the pandemic in Japan

…, S Sano, S Nakamura, M Nishimura… - Open Forum …, 2021 - academic.oup.com
Background As of March 2021, Japan is facing a fourth wave of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection. To prevent further spread of infection, sera …